Subsequent in vivo experimental models showed that the enhanced survival noted for animals implanted with TTFields-treated wild-type (WT) tumor cells was abrogated when mice were challenged with TTFields-treated STING/AIM2-double-knockdown tumor cells. The gene discussed is AIM2; the disease is neoplasm.